Lv2
160 积分 2023-07-18 加入
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
4天前
已完结
Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer
7天前
已完结
Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management
30天前
已完结
The Role of Histologic Grading and Ki-67 Index in Predicting Outcomes in Pulmonary Carcinoid Tumors
1个月前
已完结
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
1个月前
已完结
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2个月前
已完结
PL02.18 Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC
3个月前
已完结
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer
3个月前
已完结
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
3个月前
已完结
Osimertinib in ResectedEGFR-Mutated Non–Small-Cell Lung Cancer
3个月前
已完结
皖公网安备34019202002308
